

Zydus receives final approval from the USFDA for Diflunisal Tablets

Ahmedabad, 20 June 2017

Zydus Cadila has received the final approval from the USFDA to market Diflunisal Tablets in the strength of 500 mg.

It is a nonsteroidal anti-inflammatory drug (NSAID) and will be produced at the group's formulations manufacturing facility at Baddi.

The group now has more than 120 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
